CVALF
Covalon Technologies Ltd.·Healthcare
1.44
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $1.1652W H: $2.14
CVALF NEWS
businesswire.com
2d ago
Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSX: COV; OTCQX: CVALF), an advanced medical technologies company, today announced a series of important milestones reflecting the Company's growing market development and commercial momentum, and deepening engagement across the vascular access, infection prevention, and wound care sectors. Strong Engagement at Infusion Nurses Society Annual Meeting Covalon had a strong presence at the Infusion Nurses Society (INS) Annual Meeting.
businesswire.com
Apr 10
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its upcoming presence at the Infusion Nurses Society (INS) 2026 Annual Meeting taking place in Louisville, KY from April 11 – 14, 2026. The event will bring together leading clinicians, researchers, healthcare professionals and industry leaders all dedicated to advancing vascular access and infusion therapy practice. Attendees will have the opport.
businesswire.com
Mar 27
Covalon Announces Grant of Deferred Share Units
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the Company has granted an aggregate of 97,674 Deferred Share Units (“DSUs”) to four of its non-employee directors that elected to receive all or a portion of their annual directors' fees for fiscal year 2026 in DSUs as opposed to cash. The DSUs were granted under the Company's Amended and Restated Omnibus Long-Term.
businesswire.com
Mar 26
Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its fiscal 2025 Annual General and Special Meeting of Shareholders (the "Meeting") held on March 25, 2026. Shareholders voted in favour of all items of business at the Meeting and each item of business was approved by the requisite number of votes. The approved matters included.
seekingalpha.com
Mar 25
Covalon Technologies Ltd. (COV:CA) Shareholder/Analyst Call Transcript
Covalon Technologies Ltd. (COV:CA) Shareholder/Analyst Call Transcript
businesswire.com
Mar 18
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting of shareholders of the Company will be held on Wednesday, March 25, 2026 at 2:00pm Eastern Time in a virtual-only format where shareholders may attend and participate in the meeting via live webcast. The meeting will include a presentation from Covalon's CEO, Brent Ashton, with a Question and Answ.
